CS
ANAB icon

Credit Suisse’s AnaptysBio ANAB Stock Holding History

Credit Suisse’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$356K Sell
15,813
-5,280
-25% -$125K ﹤0.01% 2771
2023
Q4 		$452K Sell
21,093
-2,392
-10% -$41.3K ﹤0.01% 2779
2023
Q3 		$422K Sell
23,485
-2,463
-9% -$47K ﹤0.01% 2766
2023
Q2 		$528K Buy
25,948
+4,688
+22% +$95K ﹤0.01% 2751
2023
Q1 		$463K Buy
21,260
+1,880
+10% +$45.7K ﹤0.01% 2791
2022
Q4 		$601K Buy
19,380
+5,549
+40% +$157K ﹤0.01% 2671
2022
Q3 		$353K Buy
13,831
+96
+0.7% +$2.25K ﹤0.01% 3001
2022
Q2 		$279K Sell
13,735
-680
-5% -$15.1K ﹤0.01% 3199
2022
Q1 		$356K Sell
14,415
-288
-2% -$8.72K ﹤0.01% 3149
2021
Q4 		$511K Buy
14,703
+1,054
+8% +$33.4K ﹤0.01% 3802
2021
Q3 		$371K Buy
13,649
+2,991
+28% +$75.9K ﹤0.01% 3994
2021
Q2 		$277K Sell
10,658
-11,238
-51% -$269K ﹤0.01% 4141
2021
Q1 		$472K Sell
21,896
-19,194
-47% -$484K ﹤0.01% 3809
2020
Q4 		$882K Sell
41,090
-4,539
-10% -$110K ﹤0.01% 3417
2020
Q3 		$673K Sell
45,629
-29,337
-39% -$529K ﹤0.01% 3205
2020
Q2 		$1.68M Buy
74,966
+11,721
+19% +$214K ﹤0.01% 2521
2020
Q1 		$894K Sell
63,245
-3,846
-6% -$58.3K ﹤0.01% 2739
2019
Q4 		$1.09M Buy
67,091
+45,638
+213% +$1.08M ﹤0.01% 3056
2019
Q3 		$751K Sell
21,453
-14,559
-40% -$693K ﹤0.01% 3208
2019
Q2 		$2.03M Buy
36,012
+21,044
+141% +$1.52M ﹤0.01% 2438
2019
Q1 		$1.09M Buy
14,968
+1,207
+9% +$83.3K ﹤0.01% 2822
2018
Q4 		$878K Buy
13,761
+6,945
+102% +$516K ﹤0.01% 2886
2018
Q3 		$680K Sell
6,816
-5,026
-42% -$417K ﹤0.01% 3114
2018
Q2 		$842K Sell
11,842
-1,243
-9% -$104K ﹤0.01% 3138
2018
Q1 		$1.36M Sell
13,085
-3,278
-20% -$369K ﹤0.01% 2736
2017
Q4 		$1.65M Buy
16,363
+7,073
+76% +$521K ﹤0.01% 2597
2017
Q3 		$324K Buy
+9,290
New +$251K ﹤0.01% 3702

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Credit Suisse's ANAB Position: Q1 2024 in Review

Credit Suisse reduced its AnaptysBio (ANAB) stake by 25% in Q1 2024, selling an estimated $125K and leaving 15,813 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #2771.

Credit Suisse first reported a position in ANAB in Q3 2017 and has held it in 27 quarters since. The position peaked at $2.03M in Q2 2019. 133 funds tracked by Wall St. Rank hold ANAB as of Q1 2024.

  • Credit Suisse held 15,813 shares of AnaptysBio worth $356K as of Q1 2024.
  • Credit Suisse sold 5,280 AnaptysBio shares in Q1 2024, an estimated $125K.
  • AnaptysBio made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2771 holding.
  • Credit Suisse first reported a position in AnaptysBio in Q3 2017 and has held it in 27 quarters since.
  • Credit Suisse's AnaptysBio position peaked at $2.03M in Q2 2019.
  • 133 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.